Clinical Features, Diagnosis, and Treatment of Tuberculosis in Infants

PEDIATRICS ◽  
1994 ◽  
Vol 94 (1) ◽  
pp. 1-7
Author(s):  
Jesus G. Vallejo ◽  
Lydia T. Ong ◽  
Jeffrey R. Starke

Objective. Despite the recent resurgence of tuberculosis among children in the United States, no series of infants <1 year of age with tuberculosis has been reported in the last 20 years. This study was undertaken to describe the epidemiology, clinical, and radiographic manifestations, and response to therapy in infants <1 year of age with tuberculous disease. Methods. The medical records were reviewed for all infants age 12 months or less with a diagnosis of tuberculosis and cared for at the Children's Tuberculosis Clinic at Ben Taub General Hospital in Houston, Texas between January 1, 1985 and June 30, 1992. Results. Of the 47 infants identified, 51% were female. The median age at diagnosis was 8 months (range 3.5 to 12 months). Fifty-one percent of the infants were African-American and over one-third were Hispanic. All patients were born in the United States. Diagnosis resulted from the examination of an ill infant in 79% of cases, a case contact investigation of an adult suspected of having tuberculosis in 19%, and routine tuberculin skin testing in 2%. An adult with infectious tuberculosis who had contact with the infant was identified in 68% of cases. Intrathoracic disease alone was present in 70% of cases. Fourteen (30%) infants had extrapulmonary tuberculosis (11 central nervous system disease, 2 disseminated disease, and 1 cervical adenitis). Gastric aspirate cultures yielded Mycobacterium tuberculosis from 75% of the infants with isolated intrathoracic disease. Forty-five infants successfully completed therapy and only one death was directly related to tuberculosis. Forty-eight percent of the infants with pulmonary tuberculosis were treated with a 6-month regimen consisting of isoniazid and rifampin supplemented during the first 2 months by pyrazinamide. Eighteen infants received some twice weekly directly observed therapy mainly due to documented or suspected nonadherence. Treatment was well-tolerated; one patient (2%) developed hepatotoxicity due to isoniazid. No infant had a relapse or recurrence of disease in 6 months to 7 years follow-up for a median of 3 years (range, 6 months to 7 years). Conclusion. Most infants with tuberculosis are symptomatic at the time of diagnosis, and bacteriologic confirmation was obtained in 70% of cases. A contact investigation of the household should be initiated immediately when an infant is suspected of having tuberculosis because valuable information needed to establish the diagnosis and guide therapy in the infant may be obtained. Intensive 6-month and twice weekly directly observed therapy appear to be well-tolerated and effective for the treatment of pulmonary tuberculosis in infants.

Author(s):  
Deena Yousif ◽  
Sindhu Mohandas ◽  
Sally Ward ◽  
Ronen Zipkin

Disseminated tuberculosis (TB) in the pediatric population is relatively rare in the United States with variable nonspecific presentations. In this letter we discuss the case of 2-year-old child with a lung mass and central neurogenic hyperventilation with primary respiratory alkalosis as a rare pediatric presentation of disseminated tuberculosis with TB meningitis and pulmonary tuberculosis.


2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Ruslan Garcia

Community-acquired pneumonia (CAP) is an important cause of hospitalizations in adults. In the United States, Streptococcus pneumoniae is the most frequently identified bacterial pathogen responsible for CAP. Other etiologic pathogens of CAP vary based on the geographic region. Mycobacterium tuberculosis is an uncommon cause of CAP in the United States, while it is a principal cause in many African and Asian countries. Coinfection with Streptococcus pneumoniae and Mycobacterium tuberculosis is rare and has only been reported in the setting of underlying HIV infection in areas of high tuberculosis prevalence. Here, we report a case of CAP in the absence of HIV, where Streptococcus pneumoniae was identified on admission and delay in diagnosis of concomitant active pulmonary tuberculosis led to inappropriate isolation. In addition to a high index of suspicion, epidemiologic and radiographic findings can be helpful to recognize tuberculosis as a cause of CAP even when other pathogens have already been identified.


1993 ◽  
Vol 16 (4) ◽  
pp. 513-518 ◽  
Author(s):  
L. Slutsker ◽  
K. G. Castro ◽  
J. W. Ward ◽  
S. W. Dooley

2001 ◽  
Vol 120 (5) ◽  
pp. A381
Author(s):  
Sunil Ramrakhiani ◽  
Bruce R. Bacon ◽  
Sreelatha C. Varma ◽  
Sanjay Ramrakhiani ◽  
Adrian M. Di Bisceglie

2001 ◽  
Vol 120 (5) ◽  
pp. A381-A381
Author(s):  
S RAMRAKHIANI ◽  
B BACON ◽  
S VARMA ◽  
S RAMRAKHIANI ◽  
A DIBISCEGLIE

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 3548-3548
Author(s):  
Caitlin M O'Neill ◽  
Ulysses Gomez ◽  
Ilene C Weitz ◽  
Casey O'Connell ◽  
Howard Liebman

Abstract Background Infection with Helicobacter pylori has been implicated as an etiologic agent for the development of immune thrombocytopenia (ITP). In a systematic review of the medical literature Stasi and colleagues reported wide regional variation in the prevalence of H. pylori infection in ITP patients with significant differences in improvement in platelet count with infection eradication. The largest report on H.pylori infection in ITP patients diagnosed in the United States found a lower prevalence of infection (21.6%) than the reported seroprevalence (32.5%) for the general United States population.1 Only 1 of 15 treated patients responded eradication of their infection.1 Based upon this report the American Society of Hematology ITP guidelines do not recommend routine H. pylori testing during the evaluation of newly diagnosed patients. Los Angeles County-University of Southern California Medical Center is the largest healthcare provider in the metropolitan Los Angeles region. It services a large and ethically diverse patient population. Screening for H.pylori infection in newly diagnosed and previously diagnosed ITP patients was begun as a routine part of the diagnostic algorithm in 2008. We initiated a retrospective review of H.pylori infection in patients screened during this period. Results At the time of this report the medical records of 80 ITP patients (M/F: 22/58) have been reviewed. 68 (F/M: 52/16) patients, 51 with 1o ITP and 17 with 2ry ITP, were screened for H.pylori. The median age of the screened patients was 50 yrs (23 to 85 yrs). Patients were screened with either the H. pylori stool antigen (46 pts; 65%) or H. pylori Breath test (10 pts; 16%). 12 patients (19%) were only screened for H.pylori antibodies. Of the screened patients, 29/68 (42.6%) tested positive for H. pylori. However, there were significant ethnic and racial differences in the prevalence of infection (Table ). 27 of the 29 positive patients were treated for their infection. H. Pylori eradication was documented in 20 of 22 (91%). An additional patient was successfully treated with a second course of antibiotics. Response to therapy could not be assessed in 14 of the 27 treated patients due to treatment with concomitant ITP medications. Of the 13 patients who could be evaluated for response using IWG criteria, there were 4 (30.8%) complete responses, 1 (7.7%) partial response and no response in 8 (61.5%). All complete responders were treated within 2 months of initial presentation. At the time of this report only 3 of the 29 patients remain on ITP treatment. Conclusion There are significant ethnic and racial differences in the prevalence of H. pylori infection in ITP patients diagnosed in the greater Los Angeles metropolitan region. Despite earlier reports from New York and Miami, early identification and treatment of H. pylori infected may result in remissions up to a third of patients. 1. Michel M et al. Blood 2004; 103: 890-896. Disclosures: No relevant conflicts of interest to declare.


1997 ◽  
Vol 15 (1) ◽  
pp. 153-184 ◽  
Author(s):  
FELISSA L. COHEN

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. In the United States, TB has undergone a resurgence and the appearance of multidrugresistant TB has caused new concerns. A critical part of TB treatment is adherence to the prescribed therapy for a considerable time period. Treatment “failure” is often due to nonadherence. Many factors influence adherence to therapy in TB. This chapter reviews research in the area of adherence to the TB treatment plan in the United States and worldwide. It discusses adherence as an outcome related to treatment regimens such as directly observed therapy, patient characteristics, life and family circumstances, motivation, education, incentives, and combination strategies. Themes across studies are compared and suggestions for successful future studies are identified.


Sign in / Sign up

Export Citation Format

Share Document